Add like
Add dislike
Add to saved papers

Photodynamic therapy evaluation of methoxypolyethyleneglycol-thiol-SPIONs-gold-meso-tetrakis(4-hydroxyphenyl)porphyrin conjugate against breast cancer cells.

Magnetic field enhanced photodynamic therapy is an effective non-invasive technique for the eradication of cancer diseases. In this report, magnetic field enhancement of the photodynamic therapy (PDT) efficacy of a novel methoxypolyethyleneglycol-thiol-SPIONs-gold-meso-tetrakis(4-hydroxyphenyl)porphyrin conjugate (nano-drug) against MCF-7 breast cancer cells was evaluated. The nano-drug exhibited excellent blue and red emissions under suitable ultraviolet (380 nm) and visible (430 nm) excitations and was well taken up by the cells without any significant dark cytotoxicity after 24 h post-incubation. However, after exposure of cells to light for about 15 min, high rate of cell death was observed in a dose-dependent manner. In addition, the cells that were exposed to external magnetic field displayed higher phototoxicity than the non-exposed cells. Altogether, these results suggest that the nano-porphyrin drug system can function as a new promising magnetic-field targeting agent for theranostic photodynamic eradication of cancer diseases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app